ArticleBlood advances2026

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Jacqueline S Garcia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.